Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039026 · ClinicalTrials.gov registry record · Phase 3
Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea
A Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 377
- Enrollment target
- 20
- Study locations
NCT00039026: Completed Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, sponsored by AstraZeneca.
NCT00039026 is a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent that has completed, run by AstraZeneca. The registered enrollment target is 377 participants, above the 169-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039026, a Phase 3 study of Diabetes Mellitus, Non-Insulin-Dependent, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 377 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their required existing diabetes medication (sulfonylurea) throughout the study.
Primary Outcome
Change in HbA1c from Baseline (Day 1) to study termination (Week 30)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AC2993
Study Locations (20)
Alabama
- Pinnacle Research Group - Anniston
- Parkway Medical Center - Birmingham
- Alabama Clinical Therapeutics - Birmingham
- Eclectic Family Care - Eclectic
- Winston Physician Services - Haleyville
- Simon Williamson Clinic - Hueytown
- Extended Arm Physicians/ Southern Drug - Montgomery
- Southern Drug Research Network - Tallassee
Arizona
- Clinic of Physicians and Surgeons, Ltd. - Mesa
- ANA Ventures, LLC - Mesa
- Lovelace Scientific Resources-Phoenix - Phoenix
- Physicians at the Peak - Phoenix
- Advanced Clinical Therapeutics - Tucson
California
- Advanced Clinical Research Institute - Anaheim
- Mitchell Research Group, Inc. - Bakersfield
- William Zigrang, M.D. - Burlingame
- International Clinical Research Network - Chula Vista
- Arrowhead Regional Medical Center - Colton
Arkansas
- CAVHS - Little Rock
- Physicians Group Research Clinic, LLC - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2002-02 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
What the finished NCT00039026 record still lists
NCT00039026 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, above the 169-participant average among 5 other Diabetes Mellitus, Non-Insulin-Dependent trials with a reported enrollment target (123% higher).
The record links to 1 condition, with Diabetes Mellitus, Non-Insulin-Dependent appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00039026 names 20 study sites across 4 states, led by Alabama, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00039026 about?
NCT00039026 is a clinical study titled "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea". This is a multicenter, randomized, blinded, placebo-controlled study to assess the effects on glucose control of AC2993 as compared to placebo in patients with type 2 diabetes. Patients will be randomized into one of two AC2993 treatment arms or to placebo treatment and will continue with their requ...
What is the current status of trial NCT00039026?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 377 participants. The study started on 2002-02. Estimated completion is 2003-08.
What conditions does trial NCT00039026 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Non-Insulin-Dependent.
What interventions are being tested in trial NCT00039026?
The interventions under investigation include: Placebo (DRUG), AC2993 (DRUG).
Who is sponsoring clinical trial NCT00039026?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00039026 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Non-Insulin-Dependent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione
COMPLETED · Phase 3
-
PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA
COMPLETED · Phase 1
-
To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study
COMPLETED · Phase 4
-
Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes
COMPLETED · NA
-
Study of the Effects of Vitamin C on Patients With Type 2 Diabetes
COMPLETED · Phase 2
-
Methods for Measuring Insulin Sensitivity
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07024784 · 377 participants · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia